ArticleBMC infectious diseases2026
Pneumococcal serotype distribution and diagnostic yield of serotype-specific urinary antigen detection in adults with CAP in Switzerland, 2016-2021: a prospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStreptococcus pneumoniae remains the leading bacterial cause of community-acquired pneumonia (CAP) and a major source of morbidity and mortality in adults. Pneumococcal conjugate vaccines (PCVs) have substantially reduced invasive pneumococcal disease, but serotype replacement has led to shifts in pneumococcal CAP epidemiology. In addition, the identification of S. pneumoniae remains challenging. This study investigated pneumococcal serotype distribution, vaccine coverage, and the diagnostic yield of a serotype-specific urinary antigen detection assay (ssUAD) among adults with CAP in Switzerland between 2016 and 2021.
methodsAdult patients enrolled in the Swiss CAPNETZ cohort with available urine samples were analyzed using the Pfizer 24-serotype ssUAD assay. Results were compared with conventional diagnostic methods, including the pneumococcal urinary antigen test (pUAT) and cultures. Serotype distribution, vaccine coverage (PCV13, PCV15, PCV20 and PCV21), and temporal trends were assessed.
resultsAmong 234 CAP patients, S. pneumoniae was identified by conventional diagnostics (pUAT and cultures combined) in 37 (15.8%). The ssUAD was positive in 35 patients (15.0%). Among patients with available results from both conventional diagnostics and ssUAD (n = 161), the addition of ssUAD increased pneumococcal CAP detection from 18.6% to 29.2% (p = 0.036). Among ssUAD-positive patients, the most frequent serotypes detected by ssUAD were 3 (n = 12), 8 (n = 5), and 11A (n = 4). Based on ssUAD-derived serotype distribution, vaccine coverage was 54.3% for PCV13, 60.0% for PCV15, 91.4% for PCV20, and 85.7% for PCV21. During 2020-2021, the proportion of serotypes not covered by PCV13 increased from 10/28 (35.7%) to 6/7 (85.7%) (p = 0.018).
conclusionsThe addition of ssUAD improved S. pneumoniae detection beyond standard methods. Although based on a small number of cases, the shift toward non-PCV13 serotypes underscores the potential benefit of higher-valency vaccines such as PCV20 and PCV21 for adult pneumococcal disease prevention in Switzerland.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.